About Me

Research Interests

  • Vascular biology
  • Thrombosis
  • Atherosclerosis

Research Profile

I have a longstanding research interest in thrombosis and vascular biology with a particular interest in plasminogen activator inhibitor-1 (PAI-1) and vitronectin. At present, a major focus of my lab involves the use of pharmacological compounds to prevent adverse vascular remodeling, including atherosclerosis, restenosis after coronary stent implantation and vein graft disease. Our laboratory utilizes several animal models that allow us to study vascular remodeling under conditions relevant to human cardiovascular disease. We also employ a variety of in vitro and in vivo methods that enable us to probe the molecular and cellular mechanisms underlying intimal hyperplasia and atherosclerosis. My overall effort breakdown is: research (including mentoring of trainees) 60 percent; patient care 25 percent; teaching 5 percent, administration 10 percent.

Credentials

Position

  • Professor of Medicine and Medical Pharmacology & Physiology

Board Certifications

  • 1990 Medical License Michigan
  • 2005 Medical License Missouri

Medical

1990, MD, Clinical and Research Fellowship in Cardiovascular Medicine Mayo Clinic

Residency

1985, University of Michigan Medical Center

Fellowship

1990, Mayo Clinic Rochester, MN

Awards & Honors

  • 1978 B.S., Magna cum Laude, University of Illinois
  • 1980 Phi Beta Kappa
  • 1981 Alpha Omega Alpha
  • 1982 President, Alpha Omega Alpha, University of Illinois Chapter
  • 1982 M.D. with Honors, University of Illinois
  • 1982 Finalist, William J. Grove Award (Outstanding Graduate), University of Illinois
  • 1989 Finalist, Young Investigators' Award Competition, American College of Cardiology
  • 1990 Outstanding Achievement Award for a Subspecialty Trainee in Cardiovascular Disease (Research), Mayo Clinic
  • 1992 Winner, Young Investigator Prizes in Thrombosis, American Heart Association
  • 1994 Academic Exchange Award, American College of Cardiology/European Society of Cardiology
  • 1998 Finalist, Update in Thrombolysis 1998 Research Award Competition
  • 2004- J.W. and Lois Winifred Stafford Distinguished Chair in Diabetes and Cardiovascular Research, University of Missouri
  • 2006 Thrombosis Special Recognition Award, ATVB Council of American Heart Association
  • 2011 Visiting Professor, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
  • 2016 Chair, NIH Special Emphasis Panel ZRG1 VH-J, October 27 2016
Grants
  • NIH R01 “Roles of Plasminogen Activator Inhibitor-1 and Vitronectin in Failure of Coronary Revascularization”
  • NIH/NHLBI Program Project Grant “Molecular Genetics of Coagulation Disorders” PI: D. Ginsburg Dr. Fay is Co-Investigator (10% effort) on Project 3: (“Thrombosis and Hemostasis in Host Defense from Bacterial Infection”, PI: H. Sun)
  • NIH R44 “Improved long-term biocompatibility of coronary stents by plasma coating process” PI: M. Chen (APT Therapeutics). Missouri Life Sciences Trust Fund. “Targeting Plasminogen Activator Inhibitor-1 to Inhibit Restenosis”

Locations

1 Hospital Dr
Columbia, Missouri, 65212
United States

(573) 882-2296

Publications

  • Zuidema MY, Peyton K, Fay WP, Durante W, Korthuis, RJ: Antecedent hydrogen sulfide elicits an anti-inflammatory phenotype in postischemic murine small intestine: Role of heme oxygenase-1. Am J Physiol Heart Circ Physiol 2011;301:H888-H894. PMCID: 21666111.
  • Sidhu MS, Aggarwal K, Fay WP: Acute Isolated Right Ventricular Myocardial Infarction Masquerading as Acute Anterior Myocardial Infarction. BMJ Case Reports. 2014; doi:10.1136/bcr-2012-008087.
  • Ji Y, Fish PM, Strawn TL, Lohman AW, Wu J, Szalai AJ, Fay WP: C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts. J Thromb Haemost. 2014;12:1667-77. PMCID: PMC4194135.
  • Wu J, Strawn TL, Luo M, Wang L, Li R, Ren M, Xia J, Zhang Z, Ma W, Luo T, Lawrence DA, Fay WP: Plasminogen Activator Inhibitor-1 Inhibits Angiogenic Signaling by Uncoupling VEGF Receptor-2-αVβ3 Integrin Cross-talk. Arterioscler Thromb Vasc Biol. 2015; 35:111-120. PMCID: PMC4270947.
  • Chen N, Ren M, Li R, Deng X, Li Y, Yan K, Xiao L, Yang Y, Wang L, Luo M, Fay WP, Wu J: Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Molecular Cancer 2015; 14:140. PMCID: PMC4517418.
  • Somanna NK, Valente AJ, Krenz M, Fay WP, Delafontaine P, Chandrasekar B. The Nox1/4 Dual Inhibitor GKT137831 or Nox4 Knockdown Inhibits Angiotensin-II-Induced Adult Mouse Cardiac Fibroblast Proliferation and Migration. AT1 Physically Associates With Nox4. J Cell Physiol. 2016;231:1130-41. doi: 10.1002/jcp.25210.
  • Khoobchandani M, Katti K, Maxwell A, Fay WP*, Katti KV* (*co-senior author). Laminin Receptor-Avid Nanotherapeutic EGCg-AuNPs as a potential alternative therapeutic approach to prevent restenosis. Int J Mol Sci. 2016 Mar 1;17. doi: 10.3390/ijms17030316.
  • Ji* Y, Weng* Z, Fish P, Goyal N, Luo M, Myears SP, Strawn TL, Chandrasekar B, Wu J, Fay WP (*these authors contributed equally to this article). Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation. Arterioscler Thromb Vasc Biol. 2016;36:2167-2175. PMCID: PMC5102271.